CXCR4 and lung cancer: Plerixafor, as a CXCR4 targeted treatment for lung cancer, is well supported by preclinical or early clinical evidence as a potential therapeutics for lung cancer in combination with chemotherapy, radiotherapy, and immunotherapy.